Vivoryon Therapeutics N.V. (AMS:VVY)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
1.420
-0.020 (-1.39%)
Jul 21, 2025, 5:35 PM CET
-37.72%
Market Cap37.25M
Revenue (ttm)n/a
Net Income (ttm)-20.57M
Shares Out26.23M
EPS (ttm)-0.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,391
Average Volume43,928
Open1.460
Previous Close1.440
Day's Range1.420 - 1.468
52-Week Range1.370 - 3.000
Beta1.96
RSI38.76
Earnings DateSep 9, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 14
Stock Exchange Euronext Amsterdam
Ticker Symbol VVY
Full Company Profile

Financial Performance

Financial Statements

News

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Challenges

7 months ago - GuruFocus

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

7 months ago - GuruFocus